Axumin PET Scans: A Breakthrough for Prostate Cancer
BY MARK SCHOLZ, MD Axumin is an FDA-approved, Medicare-covered scan that can achieve early detection of recurrent prostate cancer after surgery or radiation. For years we have been able to …
Blog
Is It Possible to Substitute a Scan for Prostate Biopsy?
BY MARK SCHOLZ, MD There are two different ways to do a prostate biopsy – targeted and random. The random 12-core prostate biopsy is standard and has been in use for over …
Intelliscore ExoDx and PCA-3
BY JEFFREY TURNER, MD For patients that do have an elevated PSA, there are other screening tools that fit in nicely before doing a biopsy. A few of those are …
New Screening Tests for Prostate Cancer
By Jeffrey Turner, MD Clinically Significant Prostate Cancer The United States Preventive Services Task Force advised against routine PSA screening claiming the risks outweigh the benefits given that overtreatment of …
Elevated PSA From Screening: What to Do?
BY MARK SCHOLZ, MD The PSA assay, along with cholesterol and other tests, is a common component of the blood testing that occurs during a man’s annual physical examination. But …
Selecting the Best Therapy for Newly-Diagnosed Prostate Cancer
BY MARK SCHOLZ, MD Due to the absence of well-designed comparative studies, treatment selection for prostate cancer has been highly controversial. However, in October 2016, two landmark articles published in the New England …
Prostate Biopsy and Alternatives
BY MARK SCHOLZ, MD It seems we have a national passion for prostate biopsies. A million men are biopsied every year. Two hundred thousand of them will be diagnosed with prostate cancer …
Choosing the Best Prostate Cancer Treatment for You
By Micah Chancey & Mark Scholz, MD Surgery, Radiation, Active Surveillance, or Seed Implant? Since there are three different risk categories of newly-diagnosed prostate cancer—low, intermediate and high—optimal treatment varies. READ THE FULL …
Preventing Hormone Therapy Side Effects
BY MARK SCHOLZ, MD A number of interventions are available that can substantially reduce adverse side effects from testosterone inactivating pharmaceuticals (TIP). Side effects vary from patient to patient and are influenced by the …
Jevtana and Provenge
BY MARK SCHOLZ, MD New prostate cancer drugs come to market quite rarely because the studies mandated by the FDA cost hundreds of millions of dollars. The FDA requires these studies to randomly allocate men into …